Urokinase-type plasminogen activator receptor: a beacon of malignancy?
- PMID: 18794069
- PMCID: PMC2587046
- DOI: 10.1158/1078-0432.CCR-08-1557
Urokinase-type plasminogen activator receptor: a beacon of malignancy?
Abstract
Discriminating between benign and malignant disease is a pivotal diagnostic issue in the care of women with pelvic masses. Identification of serum biomakers that can rellably make the distinction would aid in the proper referral for patient care and may provide leads in the development of early detection strategies.
Figures

Comment on
-
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.Clin Cancer Res. 2008 Sep 15;14(18):5785-93. doi: 10.1158/1078-0432.CCR-08-0096. Clin Cancer Res. 2008. PMID: 18794088
Similar articles
-
Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer.Clin Cancer Res. 2008 Sep 15;14(18):5785-93. doi: 10.1158/1078-0432.CCR-08-0096. Clin Cancer Res. 2008. PMID: 18794088
-
Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.Bosn J Basic Med Sci. 2007 May;7(2):111-6. doi: 10.17305/bjbms.2007.3063. Bosn J Basic Med Sci. 2007. PMID: 17489744
-
Detection of urokinase plasminogen activator receptor and c-erbB-2 in sera of patients with breast and ovarian carcinoma.Clin Biochem. 2003 Oct;36(7):537-43. doi: 10.1016/s0009-9120(03)00102-4. Clin Biochem. 2003. PMID: 14563447
-
Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?Eur J Surg Oncol. 2017 Feb;43(2):252-257. doi: 10.1016/j.ejso.2016.06.002. Epub 2016 Jun 20. Eur J Surg Oncol. 2017. PMID: 27345498 Review.
-
Urokinase and its receptor: marker of malignancy?Adv Exp Med Biol. 1994;360:187-91. doi: 10.1007/978-1-4615-2572-1_25. Adv Exp Med Biol. 1994. PMID: 7872083 Review. No abstract available.
Cited by
-
Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.Neoplasia. 2010 Feb;12(2):161-72. doi: 10.1593/neo.91542. Neoplasia. 2010. PMID: 20126474 Free PMC article.
References
-
- Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2008. CA Cancer J Clin. 2008;58:71–96. - PubMed
-
- Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519–29. - PubMed
-
- Bast RC, Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883–7. - PubMed
-
- Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3:355–66. - PubMed
-
- Gohagan JK, Prorok PC, Hayes RB, Kramer BS, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials. 2000;21:251S–272S. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical